Paediatric B lymphoblastic leukaemia with hyperdiploidy and a false-positive KMT2A fluorescence in situ hybridization result.


Journal

Cancer genetics
ISSN: 2210-7762
Titre abrégé: Cancer Genet
Pays: United States
ID NLM: 101539150

Informations de publication

Date de publication:
11 2023
Historique:
received: 29 01 2023
revised: 12 06 2023
accepted: 05 09 2023
medline: 20 11 2023
pubmed: 25 9 2023
entrez: 24 9 2023
Statut: ppublish

Résumé

The dramatic improvement in the event-free survival of paediatric B-lymphoblastic leukaemia (B-ALL) has led to risk-stratified treatment. Through a combination of clinical features, cytogenetic abnormalities and assessment of treatment response, patients are stratified to receive different intensities of therapy. The presence of high hyperdiploidy (>50 chromosomes) is considered a favourable genetic feature. Conversely, KMT2A fusion genes in B-ALL are associated with a poor prognosis, resulting in intensification of treatment. We present a seven-year-old female with B-ALL, a high hyperdiploid karyotype (56 chromosomes) and KMT2A rearrangement detected on FISH, but with no productive fusion identified. Single nucleotide polymorphism (SNP) array suggested the KMT2A rearrangement was due to chromosome 11 chromothripsis. Subsequent targeted RNA fusion panel and whole transcriptomic sequencing (mRNA-seq) did not detect an expressed KMT2A fusion. Differential expression analyses of the mRNA-seq data led to clustering of this case with other hyperdiploid cases, consistent with the hyperdiploid cytogenetic results. Given the additional intensity and potential toxicity of high-risk treatment, unusual findings by chromosome analysis, FISH and/or chromosomal microarray should prompt consideration of testing for a KMT2A fusion by another method to avoid misclassification.

Identifiants

pubmed: 37742392
pii: S2210-7762(23)00167-9
doi: 10.1016/j.cancergen.2023.09.002
pii:
doi:

Substances chimiques

RNA, Messenger 0

Types de publication

Case Reports Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

80-83

Informations de copyright

Copyright © 2023. Published by Elsevier Inc.

Déclaration de conflit d'intérêts

Declaration of Competing Interest The authors have no conflicts of interest.

Auteurs

Jenna Nunn (J)

Oncology Service, Children's Health Queensland Hospital & Health Service, Brisbane, Australia.

Nandini Adayapalam (N)

Genomics Discipline, Pathology Queensland, Brisbane, Australia.

Sarbjit Riyat (S)

Genomics Discipline, Pathology Queensland, Brisbane, Australia.

Louise Seymour (L)

Pathology Queensland, Brisbane, Australia; The University of Queensland, Brisbane, Australia.

Bronwyn Williams (B)

Pathology Queensland, Brisbane, Australia.

Jacqueline Rehn (J)

Precision Cancer Medicine Theme, South Australian Health & Medical Research Institute, Adelaide, Australia.

Deborah White (D)

Precision Cancer Medicine Theme, South Australian Health & Medical Research Institute, Adelaide, Australia; Faculties of Health Science & Science, The University of Adelaide, Adelaide, South Australia, Australia.

Andrew S Moore (AS)

Oncology Service, Children's Health Queensland Hospital & Health Service, Brisbane, Australia; Child Health Research Centre, The University of Queensland, Brisbane, Australia.

Karen Tsuchiya (K)

Department of Laboratory Medicine and Pathology, University of Washington Medical Center, Seattle, WA, United States. Electronic address: Karen.tsuchiya@nationwidechildrens.org.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH